CEL-SCI Co. Forecasted to Earn FY2019 Earnings of ($0.37) Per Share (CVM)
CEL-SCI Co. (NYSEAMERICAN:CVM) – Equities researchers at Zacks Investment Research reduced their FY2019 earnings per share estimates for CEL-SCI in a note issued to investors on Monday, May 20th. Zacks Investment Research analyst J. Vandermosten now expects that the company will earn ($0.37) per share for the year, down from their previous forecast of ($0.29).
Shares of NYSEAMERICAN CVM opened at $5.02 on Wednesday. CEL-SCI has a 1 year low of $0.82 and a 1 year high of $8.47.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
Featured Article: Gross Domestic Product (GDP)
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.